Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AL-39256 Ophthalmic Suspension, 1%
AL-39256, 1% · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| AL-39256 | EXPERIMENTAL | AL-39256 Ophthalmic Suspension, 1%, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks. |
| XALATAN | ACTIVE_COMPARATOR | Latanoprost Ophthalmic Solution, 0.005%, 1 drop in the study eye(s) at 8 PM from the evening bottle (morning bottle contained vehicle and was dosed 1 drop in the study eye(s) at 8 AM) for 4 weeks. |
| Vehicle | PLACEBO_COMPARATOR | Inactive ingredients, 1 drop in the study eye(s) at 8 AM from the morning bottle and 1 drop in the study eye(s) at 8 PM from the evening bottle for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| AL-39256 Ophthalmic Suspension, 1% | DRUG | - |
| Latanoprost Ophthalmic Solution, 0.005% | DRUG | - |
| Vehicle | DRUG | Inactive ingredients used as a placebo comparator |
Inclusion Criteria: * Diagnosed with open-angle glaucoma or ocular hypertension. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Females of childbearing potential. * Other protocol-defined exclusion criteria may apply.
Top 3 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular, high elution |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Bimatoprost ophthalmic solution |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | bimatoprost |
AL-39256, 1% is an investigational small molecule eye drop developed by Alcon Inc. (ticker ALC) for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is formulated as a 1% ophthalmic suspension and has been studied in a completed Phase 2 clinical trial.
AL-39256, 1% is being developed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is an investigational therapy and is not approved for commercial use. Its Phase 2 trial enrolled 104 patients and evaluated both safety and intraocular pressure-lowering efficacy.
AL-39256, 1% is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor of the clinical program evaluating this ophthalmic small molecule for open-angle glaucoma and ocular hypertension.
AL-39256, 1% is in Phase 2 clinical development. Its single Phase 2 trial, NCT00761709, has been completed. The drug is investigational and has not been approved by the FDA for any indication.
AL-39256, 1% has been studied in one Phase 2 trial, NCT00761709, titled Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension. The trial was completed, enrolled 104 patients, was randomized, double-blind, and placebo-controlled, and included adults 18 years and older.
Yes. AL-39256 Ophthalmic Suspension, 1% is another name for AL-39256, 1%. Both refer to the same investigational small molecule eye drop developed by Alcon Inc. for open-angle glaucoma and ocular hypertension, so searches using either name point to the same asset.